Following the FDA nod in late 2023, Ogsiveo (nirogacestat) became the first approved product in the company’s portfolio and the first approved drug for treating desmoid tumors, a rare, aggressive ...

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics (NASDAQ:SWTX) revealed 9 unusual trades. Delving into ...

FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. After months of discussion, Germany’s Merck KGaA said Monday it would buy ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas.

(Reuters) -SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the ...

SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully ...

Seeking to enhance its presence in cancer drugs and the US, the German drug company Merck KGaA is buying the oncology biotech SpringWorks Therapeutics for $3.9 billion. The deal is expected to close ...